Quince Therapeutics, Inc.
QNCX
$1.05
$0.05956.01%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -40.07% | -2.64% | -467.52% | 9.02% | -60.72% |
| Total Depreciation and Amortization | -94.74% | -- | 4,300.00% | 135.29% | 623.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 32.40% | -378.10% | 2,276.66% | -49.58% | 58.85% |
| Change in Net Operating Assets | 658.00% | -92.41% | -807.46% | -150.16% | 114.15% |
| Cash from Operations | -24.25% | -50.68% | -128.35% | -134.04% | -4.16% |
| Capital Expenditure | -454.17% | -- | -- | 71.32% | 69.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 46.08% | 96.73% | 75.70% | 60.28% | -59.83% |
| Cash from Investing | 101.61% | 95.46% | 75.51% | 60.90% | -71.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -100.00% | -100.00% | 34.62% | 239.29% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -50,100.00% | 34.62% | 280.00% | 416.67% |
| Foreign Exchange rate Adjustments | 189.16% | -138.71% | -501.67% | 171.93% | -479.07% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 501.93% | -412.28% | 42.14% | -50.30% | -106.89% |